Johnson & Johnson (NYSE:JNJ) Shares Sold by First Western Trust Bank

First Western Trust Bank lessened its position in Johnson & Johnson (NYSE:JNJ) by 0.3% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 25,429 shares of the company’s stock after selling 80 shares during the period. First Western Trust Bank’s holdings in Johnson & Johnson were worth $3,941,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in JNJ. Atlantic Private Wealth LLC acquired a new stake in shares of Johnson & Johnson in the 1st quarter worth $32,000. GW&K Investment Management LLC acquired a new stake in shares of Johnson & Johnson in the 4th quarter worth $35,000. Dark Forest Capital Management LP increased its holdings in shares of Johnson & Johnson by 1,044.4% in the 4th quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock valued at $36,000 after purchasing an additional 188 shares in the last quarter. Ruedi Wealth Management Inc. purchased a new position in shares of Johnson & Johnson in the 4th quarter valued at about $42,000. Finally, Kepos Capital LP purchased a new position in shares of Johnson & Johnson in the 4th quarter valued at about $45,000. Institutional investors and hedge funds own 68.40% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on JNJ shares. Raymond James dropped their target price on shares of Johnson & Johnson from $184.00 to $179.00 and set an “outperform” rating for the company in a report on Tuesday, September 5th. Morgan Stanley reduced their price target on shares of Johnson & Johnson from $187.00 to $172.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 31st. Barclays lowered their target price on Johnson & Johnson from $175.00 to $158.00 and set an “equal weight” rating for the company in a research note on Friday. JPMorgan Chase & Co. raised their target price on Johnson & Johnson from $175.00 to $180.00 and gave the company a “neutral” rating in a report on Friday, July 21st. Finally, Credit Suisse Group lifted their price objective on Johnson & Johnson from $170.00 to $175.00 and gave the stock a “neutral” rating in a report on Friday, July 21st. Nine research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $170.65.

Johnson & Johnson Stock Up 0.0 %

NYSE JNJ traded up $0.04 on Tuesday, reaching $162.70. The stock had a trading volume of 1,430,529 shares, compared to its average volume of 13,066,552. The business has a 50 day moving average price of $166.09 and a 200 day moving average price of $161.58. The company has a current ratio of 1.12, a quick ratio of 0.88 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 1 year low of $150.11 and a 1 year high of $181.04. The company has a market capitalization of $422.85 billion, a price-to-earnings ratio of 32.93, a P/E/G ratio of 3.47 and a beta of 0.54.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Thursday, July 20th. The company reported $2.80 EPS for the quarter, beating analysts’ consensus estimates of $2.62 by $0.18. The firm had revenue of $25.53 billion for the quarter, compared to the consensus estimate of $24.63 billion. Johnson & Johnson had a return on equity of 36.72% and a net margin of 13.35%. The business’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.59 earnings per share. On average, analysts forecast that Johnson & Johnson will post 10.03 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 7th. Investors of record on Monday, August 28th were given a dividend of $1.19 per share. The ex-dividend date of this dividend was Friday, August 25th. This represents a $4.76 annualized dividend and a dividend yield of 2.93%. Johnson & Johnson’s dividend payout ratio is presently 96.36%.

Insider Buying and Selling at Johnson & Johnson

In other news, insider William Hait sold 14,698 shares of the stock in a transaction that occurred on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total value of $2,528,056.00. Following the completion of the transaction, the insider now directly owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other news, insider William Hait sold 14,698 shares of the stock in a transaction that occurred on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total value of $2,528,056.00. Following the completion of the transaction, the insider now directly owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Peter Fasolo sold 20,000 shares of the stock in a transaction that occurred on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total value of $3,406,400.00. Following the completion of the transaction, the vice president now directly owns 102,696 shares of the company’s stock, valued at $17,491,182.72. The disclosure for this sale can be found here. Insiders own 0.20% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.